Crossmark

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study

Crossref DOI link: https://doi.org/10.1186/S12933-018-0730-Z

Published: 2018-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Shigiyama, Fumika

Kumashiro, Naoki http://orcid.org/0000-0002-5432-3599
Fuchigami, Ayako

Hirose, Takahisa
Funding

Funding for this research was provided by:

Astrazeneca Japan K.K.
License Information

Text and Data Mining valid from 2018-06-12
More Information

Article History

Received: 26 April 2018

Accepted: 6 June 2018

First Online: 12 June 2018

Document is current

Any future updates will be listed below